Resistant Potato Starch to Alleviate GWI
BCCMA: Targeting Gut-Microbiome in Veterans Deployment Related Gastrointestinal and Liver Diseases; CMA5- Functional Metagenomics in GWI-related Gut Dysfunction
VA Office of Research and Development
52 participants
Feb 3, 2025
INTERVENTIONAL
Conditions
Summary
Gulf War Illness (GWI) affects an estimated 25-32% of the over 700,000 coalition troops deployed to the Persian Gulf as part of the First Gulf War. GWI causes a range of pain, fatigue, gastrointestinal, skin, neurologic, and respiratory symptoms. New treatments to reduce GWI-associated morbidity are critically needed. Research suggests a role for the gastrointestinal microbiome in mediating health, including through impacting metabolism and immunity. The disruption of this microbiome plays a role in multiple diseases, and preliminary data suggest that Veterans with GWI have altered gut microbiota. The investigators will evaluate the effectiveness of a dietary fiber prebiotic supplement intervention on improving the quality of life of Veterans with GWI.
Eligibility
Inclusion Criteria11
- Ability to provide informed written consent
- Willing to comply with all study procedures and be available for the duration of the study (including providing stool samples)
- Meeting the modified Kansas GWI case definition* with gut symptoms endorsed
- Deployed to Persian Gulf during Operations Desert Storm or Desert Shield56.Aged 50-85 years old
- Moderate to severe GWI symptoms lasting at least 6 months in a minimum of three of the six symptom domains (one of which must be fatigue). The symptom domains are:
- Pain (joint pain, muscle pain)
- Gastrointestinal (diarrhea, nausea, vomiting, cramping)
- Respiratory (persistent cough, wheezing)
- Skin (rashes)
- Fatigue (sleep problems, fatigue)
- Neurologic (memory problems, headaches, dizziness, mood changes)
Exclusion Criteria14
- A Known SARS-CoV-2 infection in the last 60 days and/or with a diagnosis of post-acute sequelae of COVID-19 (PASC, sometimes called long COVID) defined as COVID-19 symptoms lasting for greater than 6 months.
- Subjects identified as, or appearing to, lack consent capacity
- Alcohol abuse (greater than 14 drinks per week for men and 7 drinks per week for women)
- Use of investigational drugs, biologics, or devices within 30 days prior to randomization.
- Individuals who are pregnant, lactating or planning on becoming pregnant during the study.
- Diagnosed inflammatory bowel disease, Crohn's disease, or Celiac's disease
- Uncontrolled/untreated hypothyroidism
- Previous gastrointestinal surgery (colorectal surgery, gastric bypass, intestinal resection)
- Systemic antibiotics in the last 30 days
- Fecal microbiota transplant in the last 30 days
- Active dysphagia
- Allergies to any of the ingredients in MSPrebiotic
- Use of immunomodulatory medications in the last 30 days
- Any other factor, condition, or medication not listed above the Investigators believe will affect the response in the gut or the interpretation of results.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
MSPrebiotic (MSPrebiotic Inc, Carberry, Manitoba, Canada). MSPrebiotic is an unmodified resistant starch derived from potatoes (Solanar tuberosum). It consists of 20% amylose and 80% amylopectin forming granules the stomach and small intestine are unable to digest allowing for absorption in the colon. MSPrebiotic is consumed by mixing 10g into cold or room temperature foods or beverages; it is not to be heated. Participants will be instructed to take MSPrebiotic 2 or more hours before or after consuming any medications.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05820893